All Imaging & Diagnostics articles – Page 3
-
NewsNew PET tracer could lead to better ALS and Alzheimer’s diagnosis
New preclinical data on ACI-19626, a first-in-class PET tracer for imaging TDP-43 pathology, shows potential to greatly improve early diagnosis and treatment of multiple neurodegenerative diseases.
-
NewsBrain’s circHomer1 RNA offers insights for future neurological treatments
A circular RNA called circHomer1 has been found to play a vital role in forming and adjusting synapses in developing mouse brains, revealing an overlooked mechanism that helps visual neurons respond to changes in sensory input.
-
ArticleBuilding reliable organoid models for human-relevant drug discovery
Organoids are changing the landscape of biomedical research, with automation and AI driving new levels of consistency, scalability and human relevance. Aaron Risinger of Molecular Devices discusses how these technologies are advancing precision medicine – and the challenges that remain.
-
NewsSPIRAL device offers safer, smarter drug delivery to the brain
Scientists have created a flexible brain implant, called SPIRAL, capable of delivering drugs to multiple regions with pinpoint accuracy.
-
NewsImproving brain resilience: Rab proteins and future treatments
New research has discovered how Rab proteins control the delivery of critical supplies to strengthen neural connections, providing researchers with important insights into memory formation and potential strategies for Alzheimer’s resilience.
-
NewsHow nanocarriers and VLPs are uniting to fight cancer
Innovations in nanomedicine are merging to redefine precision oncology. From virus-like particles to magnetic nanoparticles, integrated delivery systems are showing powerful potential for new, targeted cancer treatments.
-
ArticleEye movements as objective biomarkers: accelerating CNS drug development
Measuring disease progression remains one of the biggest hurdles in CNS drug development. Eye movements, now trackable with just a laptop and webcam, are emerging as a sensitive and scalable biomarker that could transform how trials are designed and therapies reach patients.
-
NewsDDHD2 enables neurons to synthesise and burn fat for energy
Scientists have discovered that neurons can burn and make their own fats for energy – a finding that could lead to new treatments for rare and currently untreatable brain diseases.
-
NewsNew nanotherapy clears amyloid-β reversing Alzheimer’s in mice
Researchers have developed bioactive nanoparticles that restore the brain’s blood-brain barrier and clear toxic proteins, reversing Alzheimer’s symptoms in mice and offering a promising new approach to treating the disease.
-
NewsScientists track amyloid plaques in living mice for first time
A new fibre-optic method lets researchers monitor amyloid plaque buildup in living, freely moving mice – offering a minimally invasive way to track Alzheimer’s disease progression and test potential therapies.
-
ArticleFrom data to therapy: emerging tech driving cancer drug discovery
Multiomics, AI and liquid biopsies are giving researchers real-time insight into tumour biology and enabling more personalised cancer therapies. Find out how these technologies are advancing biomarker discovery, improving patient stratification, and guiding the design of new treatments.
-
NewsNew therapies boost deep brain stimulation accuracy in epilepsy
In a new study, researchers have discovered that deep brain stimulation targeting the centromedian nucleus could help patients with drug-resistant epilepsy improve seizure control.
-
News
Single-cell technique tracks boron in live tumour cells
Researchers at the University of Birmingham have developed a single-cell technique to track boron inside live tumour cells – making Boron Neutron Capture Therapy more effective in treating head and neck cancers.
-
NewsKey newborn liver cells could boost paediatric gene therapy
A small subset of newborn liver cells – known as clonogenic hepatocytes – drives over 90 percent of adult liver growth. New research shows how targeting these cells early could improve the effectiveness and durability of paediatric gene therapies.
-
NewsChronic neuron overactivation drives Parkinson’s cell death
New research from Gladstone Institutes shows that chronic overactivation of dopamine-producing neurons can directly trigger their death, offering new insights into why these cells deteriorate in Parkinson’s disease which could lead to potential therapies to slow its progression.
-
NewsNon-invasive method images brain development in juvenile mice
Stanford researchers have developed a non-invasive method to make juvenile mice’s skin transparent, allowing repeated imaging of developing neural circuits. The breakthrough could be used to develop new treatments for neurodevelopmental disorders.
-
News
New imaging technique tracks obesity drug tirzepatide in cells
Scientists have developed fluorescent probes that reveal how dual agonist drugs like tirzepatide target cells in the pancreas and brain, offering new insights into diabetes and obesity treatments.
-
NewsFrom graphene to grey matter: tech that supercharges brain organoids
Researchers at UC San Diego have discovered a graphene-based technology that accelerates the maturation of human brain organoids, offering a safer, non-invasive way to model diseases like Alzheimer’s.
-
NewsResearchers identify early intervention target for cerebral palsy dystonia
Researchers have developed an easy-to-use method for measuring leg dystonia in children with cerebral palsy – allowing doctors to personalise treatments more effectively.
-
ArticleChallenges in developing robust potency assays for ADCs
Developing robust potency assays for Antibody-Drug Conjugates (ADCs) is crucial for ensuring their clinical success, but designing assays that meet both technical and regulatory standards is challenging. Here, Abzena’s CSO Campbell Bunce explores the complexities of assay development and the importance of ensuring accuracy, consistency and regulatory alignment for ADCs ...